⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111921 | 1.00 | — | — | |
| SCHEMBL1086708 | 1.00 | — | — | |
| SCHEMBL567846 | 1.00 | — | — | |
| SCHEMBL1086707 | 1.00 | — | — | |
| SCHEMBL567847 | 1.00 | — | — | |
| SCHEMBL1541403 | 1.00 | — | — | |
| SCHEMBL7942107 | 0.96 | — | — | |
| SCHEMBL1112131 | 0.96 | — | — | |
| SCHEMBL4273374 | 0.96 | — | — | |
| SCHEMBL1112133 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107466322-B | Mutant transaminases and methods and uses related thereto | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-110809573-B | Vinyl compound, ultraviolet absorber and resin composition | 株式会社日本触媒 | 2022-03-08 | — | — | CN | disclosed |
| CN-114072439-A | Curable composition and resin composition for stereolithography comprising same | 株式会社可乐丽 | 2022-02-18 | — | — | CN | disclosed |
| CN-113993497-A | Curable composition and resin composition for stereolithography comprising same | 株式会社可乐丽 | 2022-01-28 | — | — | CN | disclosed |
| CN-110809573-A | Vinyl compound, ultraviolet absorber and resin composition | 株式会社日本触媒 | 2020-02-18 | — | — | CN | disclosed |
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2308812-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2014-02-26 | — | — | EP | disclosed |
| US-20080076779-A1 | Reducing platelets in mammals blood and preventing/treating pro-thrombotic conditions and diseases via inhibitors of anti-apoptotic Bcl-2 family protein members | ABBVIE INC. | 2008-03-27 | — | — | US | disclosed |
| WO-2008030836-A2 | BCL INHIBITORS TREATING PLATELET EXCESS | ABBOTT LABORATORIES (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| EP-1685119-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049594-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |